Brownlie, R.J., Carrasco Hope, H., Wright, D. et al. (3 more authors) (2026) Phospho-enol pyruvate carboxykinase inhibition limits effector function in inflammatory T cells. Frontiers in Immunology, 17. 1706167. ISSN: 1664-3224
Abstract
Introduction: Following antigenic stimulation, T cells switch from a catabolic metabolic state maintained by low levels of nutrient uptake to an anabolic metabolism that sustains the biosynthetic and energetic demands of clonal expansion, differentiation, and effector function. Much progress has been made in understanding the transcriptional and enzymatic regulation of activated T cell metabolism. However, less is understood of the role for regulators of anaplerosis and cataplerosis such as phospho-enol pyruvate carboxykinases (PEPCK) in T cells.Methods: Assessment of PEPCK expression in mouse T cells was performed. Pharmacological inhibitors were used to assess functional and metabolic roles for PEPCKs in T cell activation.Results: We show that mitochondrial PEPCK (PEPCK-M) is upregulated following T cell activation, while cytosolic PEPCK-C was not detected. The PEPCK inhibitors limited CD8+ T cell cytotoxic capacity and both CD4+ and CD8+ T cell inflammatory cytokine production. The suppression of T cell effector functions by PEPCK inhibitors was associated with decreased maximal mitochondrial respiration.Discussion: These data suggest that PEPCKs act to modulate mitochondrial metabolism, supporting effector function in T cells.
Metadata
| Item Type: | Article |
|---|---|
| Authors/Creators: |
|
| Copyright, Publisher and Additional Information: | © 2026 Brownlie, Carrasco Hope, Wright, Cook, Perales and Salmond. This is an open access article under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | immunometabolism, PEPCK, phospho-enol pyruvate carboxykinases, T cell, T cell activation |
| Dates: |
|
| Institution: | The University of Leeds |
| Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) |
| Funding Information: | Funder Grant number Cancer Research UK Supplier No: 138573 C55663/A23269 |
| Date Deposited: | 24 Apr 2026 10:47 |
| Last Modified: | 24 Apr 2026 10:47 |
| Status: | Published |
| Publisher: | Frontiers Media |
| Identification Number: | 10.3389/fimmu.2026.1706167 |
| Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:240427 |
Download
Filename: 2026-Frontimmunol.pdf
Licence: CC-BY 4.0

CORE (COnnecting REpositories)
CORE (COnnecting REpositories)